iReceptor and FAIR COVID-19 AIRR-seq data

Interested in a list of relevant publications that have cited iReceptor and the AIRR Data Commons as a platform for sharing COVID-19 AIRR-seq data, check out this twitter thread by iReceptor Technical Director Brian Corrie describing the history of COVID-19 data sharing through third party publications and citations!

The list of papers citing iReceptor for COVID-19 data storage or data reuse (as of 2021-11-26) is below:

  1. C. Schultheiß et al., “Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease,” Immunity, vol. 53, no. 2, pp. 442-455.e4, Aug. 2020.
  2. J. D. Galson et al., “Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures,” Front. Immunol., vol. 11, p. 3283, Dec. 2020.
  3. D. Simnica et al., “Landscape of T-cell repertoires with public COVID-19-associated T-cell receptors in pre-pandemic risk cohorts,” Clin. Transl. Immunol., vol. 10, no. 9, p. e1340, Jan. 2021.
  4. R. R. Goel et al., “mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern,” Science (80-. )., Dec. 2021.
  5. A. Mohamad-Gabriel Alameh et al., “Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses,” Immunity, vol. 0, no. 0, pp. 1–16, Nov. 2021.
  6. P. Meysman, A. Postovskaya, N. De Neuter, B. Ogunjimi, and K. Laukens, “Tracking SARS-CoV-2 T cells with epitope-T-cell receptor recognition models,” bioRxiv, p. 2020.09.09.289355, Sep. 2020.
  7. M. Kuchroo et al., “Multiscale PHATE Exploration of SARS-CoV-2 Data Reveals Multimodal Signatures of Disease,” bioRxiv, p. 2020.11.15.383661, Nov. 2020.
  8. M. Heming et al., “Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid,” Immunity, vol. 54, no. 1, pp. 164-175.e6, Jan. 2021.
  9. R. A. Porritt et al., “HLA class I–associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in children,” J. Clin. Invest., vol. 131, no. 10, May 2021.
  10. A. J. Schmitz et al., “A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants,” Immunity, vol. 54, no. 9, pp. 2159-2166.e6, Sep. 2021.
  11. J. Y. Humrich, J. P. Bernardes, R. J. Ludwig, D. Klatzmann, and A. Scheffold, “Phenotyping of Adaptive Immune Responses in Inflammatory Diseases,” Front. Immunol., vol. 11, p. 3010, Nov. 2020.
  12. F. P. Caruso, G. Scala, L. Cerulo, and M. Ceccarelli, “A review of COVID-19 biomarkers and drug targets: resources and tools,” Brief. Bioinform., vol. 22, no. 2, pp. 701–713, Mar. 2021.